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Background: HIV-1 co-receptor usage may play a critical role in AIDS pathogenesis. Information
on viral tropism in HIV-1 seroconverters is scarce, as is the relationship with transmission of drug-
resistant viruses.
Methods: All consecutive HIV-1 seroconverters seen between January 1997 and December 2005 in 17
Spanish hospitals were retrospectively analysed. V3 loop amino acid sequences derived from plasma
RNA at the time of initial diagnosis were used to predict co-receptor usage. Major drug resistance
mutations, plasma HIV RNA, CD4 counts and HIV subtype were considered for subsequent analyses.
Results: A total of 296 HIV-1 seroconverters were identified (84% male; median age 30 years; 61%
homosexual men). Median estimated time from infection was 7 months (interquartile range, 3–11).
Primary drug resistance mutations were seen in 12.5%, being 9.5% for nucleoside reverse transcriptase
inhibitors (NRTI), 4.4% for non-NRTI (NNRTI) and 3% for protease inhibitors (PI). Twenty-four (8.1%)
carried non-B subtypes. HIV tropism could be characterized in 203 seroconverters (69%). X4 viruses
(either pure or dual/mixed R5/X4) were recognized in 35 (17.2%). There was no association between
HIV tropism and mean plasma HIV RNA (4.5 versus 4.4 log copies/mL in R5 versus X4, respectively;
P 5 0.45) or mean CD4 counts (594 versus 554 cells/mm3, respectively; P 5 0.48). The proportion of X4
viruses did not differ in patients infected with wild-type or drug-resistant viruses (17% versus 18%,
P 5 1). Intravenous drug users tended to show X4 viruses more frequently than individuals infected by
sexual relationships (35.7% versus 16.5%, respectively; P 5 0.073). After 12 months of follow-up in 78
seroconverters who did not start antiretroviral therapy, more pronounced increases in plasma HIV RNA
(15056 versus 23430) and declines in CD4 cell counts (2126 versus 260) were seen in X4 compared
with R5 carriers.
Conclusions: A significant proportion of recent HIV-1 seroconverters harbour X4 viruses (17.2%),
without any evidence of association between co-receptor usage, transmission of drug-resistant
viruses and HIV subtype.
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Introduction
Since the publication of the first report proving that drug-resist-
ant HIV-1 could be efficiently transmitted,1 surveillance of
drug resistance in antiretroviral-naive chronically HIV-infected
individuals or recent seroconverters has provided relevant infor-
mation about the extent of drug resistance in a geographical
region and trends over time.2 – 8 Moreover, it has allowed us
to monitor the spread of new drug-resistant variants within a
community8,9 and track the source of new infections.10,11
The overall prevalence of primary HIV drug resistance in
Western countries is currently around 10–15%, with some
differences between regions and time periods.2 – 8 In Spain,
studies conducted over the last decade have shown a steady
decline in the rate of genotypic resistance among recent HIV-1
seroconverters between 1997 and 2000.7 The prevalence has
remained fairly stable since then.11 Surveys among recently
HIV-1-infected persons are of particular interest, considering
that some drug resistance mutations may become undetectable
over time and due to the implications of primary drug resistance
for the design of first-line therapies.9,12,13
Different classes of entry inhibitors are currently being tested
to be part of the antiretroviral armamentarium. Enfuvirtide, a
fusion inhibitor, has been the first molecule within this family to
obtain approval.14 Co-receptor antagonists are in the late phases
of clinical development, although the development of these
compounds (i.e. aplaviroc) has been halted because of safety
concerns. CCR5 antagonists inhibit HIV binding to CCR5, pre-
venting the virus from entering target cells.15,16 In general, most
HIV variants isolated from drug-naive, chronically HIV-infected
individuals use CCR5 along with CD4 to gain entry into cells.17
On the contrary, viruses able to use CXCR4 co-receptors tend to
emerge later over the course of HIV infection, being recognized
in nearly half of patients in advanced disease stages.18 Given
their mechanism of action, the determination of HIV tropism
before the introduction of co-receptor antagonists has been man-
datory so far. More epidemiological studies assessing the preva-
lence of HIV-tropic variants in different populations are needed
to identify the most suitable candidates for these new com-
pounds. Studies assessing the role of current antiretroviral drugs
and/or resistance mutations on virus co-receptor usage are par-
ticularly needed, since these compounds will be often used in
antiretroviral-experienced patients and/or in subjects with
drug-resistant viruses. Herein, we have assessed the prevalence
of virus co-receptor usage in a large cohort of recent HIV sero-
converters in Spain and their possible association with drug
resistance mutations, HIV subtypes, viral load and CD4 counts.
Patients and methods
Study population
All consecutive newly HIV-1-infected individuals seen between
January 1997 and December 2005 in 17 different hospitals dis-
tributed across Spain were examined. Subjects with recent HIV
seroconversion were defined according to the following criteria: (i)
individuals with detectable plasma HIV-RNA together with negative
or indeterminate HIV antibody test with or without accompanying
typical symptoms; (ii) reactivity using the AXSYM HIV Ag/Ab
Combo assay (Abbott Laboratories, Madrid, Spain), with positive
HIV p24 antigen detection and negative antibodies confirmed by
western blot or (iii) seropositivity for HIV-1 infection (reactive
ELISA and western blot) being negative on a previous test per-
formed within the prior 12 months.
Sociodemographic data were recorded for each individual using
a questionnaire and from hospital clinical charts. Plasma HIV-RNA
was measured using the third generation bDNA assay (Versant v3.0,
Bayer, Barcelona, Spain), and CD4 counts were determined by flow
cytometry (Coulter, Madrid, Spain). For a subset of patients, viral
load and CD4 counts were also available 1 year after HIV diagnosis
and were used for longitudinal analyses. The study was approved by
the Ethics Committees of the participating centres.
Drug resistance mutations
Drug resistance mutations were examined in plasma specimens at
the time of initial diagnosis. Genetic sequence analyses of both
HIV-1 reverse transcriptase (RT) and protease genes were carried
out in plasma using the Viroseq HIV-1 kit (Abbott Laboratories,
Madrid, Spain) and an automatic sequencer (ABI Prism 3100;
Celera Diagnostics, Madrid, Spain) following the manufacturer’s
instructions. Analyses were conducted including major or primary
drug resistance mutations recorded in the latest International AIDS
Society-USA panel list (www.iasusa.org, last update in September
2006).19
V3 sequence analysis and viral tropism determination
Determination of HIV-1 tropism was retrospectively performed in
those individuals with enough plasma stored at 2808C for further
genetic characterization on the HIV-1 env gene. Genotypic V3 ana-
lyses were performed using an RT–PCR, with E80 (50-CCA ATT
CCC ATA CAT TAT TGT G-30) and E105 (50-GCT TTT CCT ACT
TCC TGC CAC-30) as outer primers. Subsequently, a nested PCR
with ES7 (50-CTG TTA AAT GGC AGT CTA GC-30) and E125
(50-CAA TTT CTG GGT CCC CTC CTG AGG-30) as inner primers
was done. Conditions for PCR reactions were as follows: 488C for
45 min; 948C for 2 min; 35 cycles at 948C for 15 s, 558C for 30 s
and 728C for 30 s and 728C for 7 min for the RT–PCR reaction.
Then, 948C for 3 min; 35 cycles of 948C for 30 s, 558C for 30 s and
728C for 1 min and 728C for 7 min for the nested PCR reaction.
PCR amplicons were purified using High Pure PCR Product
Purification Kit (Roche, Mannheim, Germany) and directly sequenced
in the ABI PRISM 3100 Genetic Analyser using the ABI PRISM
Rhodamine Terminator reaction kit (Applied Biosystems, Foster City,
CA, USA). Nucleotide sequences were edited with the Sequence
Navigator software (Applied Biosystems).
For the prediction of HIV tropism, bioinformatic score methods
based on support vector machines (SVM) were used.16 Basically,
this procedure predicts HIV-1 co-receptor usage from the net charge
of the V3 loop amino acid sequence of env. The tool is freely avail-
able at the website: http://genomiac2.ucsd.edu:8080/wetcat/. A posi-
tive predictive value of 90% has been reported for SVM methods
using phenotypic assays as reference.20 In a similar population, a
phenotypic tropism assay (Phenoscript-ENV Tropism Recombinant
assay, Eurofins-Viralliancew, Paris, France) was used to validate the
genotypic results, as previously described.21,22
Phylogenetic analyses
For subtyping, pol sequences from recent seroconverters were aligned
with HIV-1 group M reference sequences (http://www.hiv.lanl.gov/
content/hivdb/SUBTYPE_REF/Table1.htlm) using the CLUSTAL
X method (MegAlign, Lasergene, DNASTAR Inc., Madison, WI,
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USA). Phylogenetic analyses were performed using the PHYLIP soft-
ware package (version 3.5c; J. Felsenstein, University of Washington,
Seattle, WA, USA). Evolutionary distances were estimated using
Dnadist (Kimura two-parameter method), and phylogenetic relation-
ships were determined using the neighbour-joining method.
Statistical analyses
Baseline characteristics of the study population were recorded as
percentages, mean+ SD or median values and 25–75% interquar-
tile ranges (IQR). The rate of drug resistance mutations and the
proportion of patients infected by X4 or R5 viruses were recorded
as absolute numbers and percentages. The Student’s t-test was used
to compare quantitative variables, whereas the x2 test was used to
compare categorical parameters. Non-parametric tests were used to
assess the significance of any association between R4 tropism and
viral load and/or CD4 counts at baseline and after 12 months of
follow-up. Differences were considered as significant if P values
were below 0.05. All reported P values were two-sided.
Results
A total of 296 recent HIV seroconverters were identified during
the 9 year study period. Their median age was 30 years; 84%
were men, most of whom had been infected through homosexual
relationships. The median estimated time from exposure to the
initial diagnosis of HIV infection was 7 months (IQR, 3–11).
Other baseline characteristics of the study population are
recorded in Table 1.
The overall rate of primary drug resistance mutations was
12.5% (37/296). By antiretroviral drug class, drug resistance
was as follows: 9.5% (28) for nucleoside reverse transcriptase
inhibitors (NRTIs), 4.4% (13) for non-NRTIs (NNRTIs) and
3% (9) for protease inhibitors (PIs). The most frequent changes
in the RT gene were at position 215, with revertant forms found
in 11 and 215Y in five individuals. Other common changes were
M41L (n ¼ 11), V118I (n ¼ 6), M184V (n ¼ 2), K103N
(n ¼ 11) and Y181C (n ¼ 2). At the protease gene, the most
common resistance mutations were M46I/L (n ¼ 4), V82A
(n ¼ 5) and L90M (n ¼ 4).
Phylogenetic analyses identified 24 samples with non-B sub-
types (8 CRF14_BG, 4 CRF03_AG, 3 CRF12_BF, 3 C, 3 G, 2 F
and 1 A). It is noteworthy that all individuals newly infected
with non-B variants were identified during the last 3 years.
Moreover, acquisition of HIV-1 had occurred following needle
sharing in all subjects infected with CRF14_BG, whereas other
non-B variants had been acquired through heterosexual inter-
course. In contrast, most seroconverters infected with HIV-1
clade B were homosexual men (P, 0.001).
HIV-1 tropism could be estimated using V3 genetic
sequences generated in 203 patients (69%). Insufficient plasma
(n ¼ 88) or assay failure (n ¼ 5) precluded obtaining results in
the remaining 203 patients. In 14 patients, all carrying non-B
subtypes, V3 sequences could not be generated or were con-
sidered inadequate for viral co-receptor assessment. Large
genetic heterogeneity in the viral envelope gene most likely
explained it. Overall, the proportion of patients infected with X4
viruses (either pure or dual/mixed X4/R5) was 17.2% (35/203).
Primary drug resistance mutations were seen in 10.8% (22/203)
of the study population with known co-receptor usage. Overall,
5% (10/203) were infected with non-B subtypes. A total of 35
individuals, from a similar population, with results of HIV
tropism inferred from V3 sequences could be tested using a
phenotypic recombinant tropism assay, and the results were
concordant in 30 (86%) cases. In the remaining five subjects,
the phenotypic test showed the presence of X4/R5 dual/mixed
viruses, whereas the genotypic analyses concluded that there
were only R5 viruses. Thus, overall, the concordance between
genotypic and phenotypic results of the tropism tests used in
this study was good.
The distribution of X4 viruses did not differ comparing sub-
jects with acute HIV-1 infection (6/34) and the rest of the recent
seroconverters, including those with more than 6 but less than
12 months from initial exposure (12/67). None of the 10 patients
infected with non-B subtypes harboured X4 viruses (P ¼ 0.14).
There was no association between HIV tropism and mean
plasma viral load (being 4.4 versus 4.5 HIV RNA log copies/mL
in X4 and R5, respectively; P ¼ 0.7). Moreover, mean CD4
counts did not differ significantly between patients harbouring
X4 and R5 viruses (554 versus 595 cells/mm3, respectively;
P ¼ 0.5). Finally, the prevalence of drug resistance did not
differ in patients with X4 and R5 viruses (11.8% versus
11%, respectively; P ¼ 1). Neither was an association detected
between specific drug resistance mutations and the presence of
X4 variants (Table 2). However, individuals who acquired HIV
through intravenous (iv) drug use tended to show X4 viruses
more frequently than subjects infected through sexual relation-
ships (35.7% versus 16.5%, respectively; P ¼ 0.072).
A total of 106 recent seroconverters with known co-receptor
usage completed a further 12 months of follow-up and had com-
plete information recorded quarterly on viral load and CD4
counts. Overall, 28 (26.4%) of them fulfilled criteria to initiate
antiretroviral therapy, following international guidelines in place
at each time point. For the remaining 78 seroconverters, plasma
Table 1. Main characteristics of the Spanish HIV-1 seroconverter
cohort (n ¼ 296)
Male gender 248 (83.7%)
Median age (years) 30 (26–36)
Risk group
homosexual men 180 (60.8%)
heterosexuals 58 (19.6%)
iv drug users 32 (10.8%)
blood transfusion 1 (0.3%)
unknown 25 (8.5%)
Median time from infection (months) 7 (3–11)
Median CD4 count (cells/mm3) 571 (398–732)
Median CD4 count (%) 26 (19–34)
Median viral load (log HIV RNA copies/mL) 4.67 (4.1–5.1)
Drug resistance mutations
NRTI 28 (9.5%)
NNRTI 13 (4.4%)
PI 9 (3%)
any 37 (12.5%)
HIV-1 non-B subtypes 24 (8.1%)
X4 viral tropism (pure or dual/mixed R5/X4)a 35 (17.2%)
Percentages or IQR are shown in parentheses.
aData available from only 203 patients.
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HIV RNA increased a median of 5056 (IQR, 218 310 to
41 492) copies/mL in X4 carriers, whereas it declined a median
of 3430 (IQR, 248 464 to 5679) copies/mL in subjects with R5
variants (P ¼ 0.092). Consistent with this trend in viral
load changes, median CD4 declines at 12 months of follow-up
were more pronounced in X4 than in R5 carriers (126 versus 60
cells/mm3, respectively; P ¼ 0.696) (Table 3).
Discussion
This study assessed the prevalence and clinical correlates of
CXCR4 tropism in a relatively large population of recent HIV
seroconverters. The proportion of X4 viruses and R5/X4 dual
tropic viruses in this population was around 18%, a rate quite
similar to that reported in studies conducted in drug-naive,
chronically HIV-infected individuals.17,18,23,24 To our knowledge
this is the first description of HIV-1 co-receptor usage in a large
group of individuals with recent seroconversion. Given that it is
generally believed that HIV transmission, at least following
vaginal or rectal sexual intercourse, is largely dependent on
initial infection of cells harbouring CCR5,25,26 our results are
somewhat unexpected. The pivotal role of R5 viruses as respon-
sible for most initial HIV infections is supported by the fact that
individuals homozygous for the D32 CCR5 deletion seem to be
‘resistant’ to HIV-1 infection,27,28 with only anecdotal reports of
infections occurring by X4 viruses.29,30
In our study, recent HIV-1 seroconverters with X4 viruses
did not show higher plasma HIV-RNA or lower CD4 counts at
the time of initial diagnosis than individuals with R5 viruses.
However, the subset of 78 subjects who completed 12 months
of follow-up without undergoing antiretroviral therapy showed
dichotomous behaviour; X4 carriers showed an increase in
plasma viraemia, whereas subjects with R5 viruses showed a
decline. Accordingly, more pronounced CD4 declines were seen
in the former group compared with the latter. The relatively
small size of the study population most likely prevented statisti-
cal significance from being reached and a larger group of
patients is required to confirm these data. Altogether, these find-
ings are consistent with the postulated increased cytopathic
effect of X4 compared with R5 viruses,31 as well as with their
higher replication32 and accelerated progression to AIDS.23,33,34
The prevalence of X4 viruses among individuals who
acquired HIV parenterally (all but one were iv drug users in our
cohort) was more than doubled compared with individuals
exposed through sexual relationships (35.7% versus 16.5%,
respectively; P ¼ 0.072). The limited size of the study popu-
lation most likely prevented statistical significance from being
reached. A similar finding has recently been noticed by others.17
The mucosal epithelium of the vagina and ectocervix as well
as the glans penis and inner foreskin in men consists of stratified
squamous epithelial cells interspersed with immature
Langerhans cells that express CD4 and CCR5, on their surface,
favouring infection by R5 viruses.35 The expression of CCR5,
but not CXCR4, on intestinal epithelial cells may also be rel-
evant to the preferential transmission of R5 viruses via the rectal
route.36 However, during HIV infection via the blood, as in
injection drug users sharing needles or haemophiliacs, the size
of the inoculum is larger and the target cells different, allowing
X4 viruses to establish infection more easily.
Transmission of drug-resistant HIV-1 occurs in 10–15% of
newly infected individuals in Western countries.2– 9 Given that vir-
ological failure may occur more frequently in subjects treated with
regimens including drugs for which resistance is present,8,12,13
Table 2. Main differences between HIV-1 recent seroconverters infected with X4 or R5 tropic viruses
R5 (n ¼ 168) X4 (n ¼ 35) P value
Median age (years) 31 33 0.172
Male gender (%) 90.4 85.7 0.407
Estimated length of HIV infection (months) 7.8 7.1 0.416
Route of infection (%)
sexual 84.5 16.5 0.072
iv drug use 64.3 35.7
Mean viral load (HIV RNA log copies/mL) 4.5 4.4 0.451
Mean CD4 count (cell/mm3) 595 554 0.489
Patients with HIV-1 non-B subtypes (%) 6.1 0 0.214
Patients with drug-resistant viruses (%) 11 11.8 1
Table 3. Evolution of virological and immunological parameters in 106 HIV-1 recent seroconverters during 12 months of follow-up
R5 (n ¼ 88) X4 (n ¼ 18) P value
Antiretroviral treatment (%) 23 (26) 5 (27.7) 0.356
DCD4 (cells/mm3)a 260 (2172/þ42.7) 2126 (2181/þ23) 0.696
DPlasma HIV RNA (copies/mL)a 23430 (248464/þ5679) þ5056 (218310/ þ 41492) 0.092
DPlasma HIV RNA (log copies/mL)a 20.14 (20.45/þ0.11) þ0.1 (20.37/þ0.33) 0.288
aOnly for those individuals without antiretroviral therapy. Results are expressed as medians and IQR.
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current guidelines recommend drug resistance testing before initi-
ating antiretroviral therapy. Overall, drug-resistant viruses tend to
be less fit than wild-type strains, and some resistance mutations
may compromise virus replication more than others, which might
explain their differential transmission efficiency.37,38 However,
recent reports have highlighted that some patients failing antiretro-
viral therapy may show highly replicative X4 viruses despite car-
rying multiple resistance mutations32 and that efficient
transmission of drug resistance may occur with X4 viruses.10 In
such cases, hypothetically, CXCR4 co-receptor usage could
provide an advantage for replication and transmission to
drug-resistant strains. If so, an association between X4 tropism
and drug resistance might be recognized in recent HIV-1 serocon-
verters. This was not confirmed in our study, since X4 viruses
were equally represented in patients who acquired HIV-1 with or
without drug resistance. Neither could any association with some
specific drug resistance mutations be detected. Our data in recent
HIV seroconverters are in agreement with those obtained in a
large study recently carried out in chronically HIV-infected indi-
viduals with and without prior antiretroviral exposure,18 in which
the prevalence of X4 viruses did not differ in patients with and
without resistance mutations.
Our study could not answer appropriately whether an associ-
ation between HIV-1 subtypes and co-receptor usage exists,
since the proportion of patients with non-B clades in our cohort
was too small. Nevertheless, none of the 10 individuals with
non-B viruses harboured X4 variants. Although an association
between X4 tropism and specific subtypes (i.e., clade D and
CRF14_BG) has been proposed in some studies,39,40 it has not
been confirmed by others.18 Of note, all five subjects with
CRF14_BG and one with clade D in our study carried R5
viruses.
Another potential limitation of our study is that HIV tropism
was estimated using a bioinformatic tool which predicts
co-receptor usage based on genotypic data rather than by using
phenotypic assays. Some rapid, high-throughput recombinant
co-receptor phenotype assays have recently been developed, and
at least two are now commercially available,16 the Monogram
Biosciences PhenoSense HIV entry assay41,42 and the
Eurofins-Viralliance Tropism Recombinant test.21,22 Far from
perfect, their disagreement is substantial43 and the proportion of
samples for which results cannot be obtained is still significant,
particularly when testing non-B subtypes.18,21,22 Given that
HIV-1 tropism is largely driven by the amino acid charges
within the third hypervariable (V3) region of gp120, sequence
data have been used to infer tropism behaviour with remarkable
success.16,44,45 The vector machine system (VMS) we used in
our study is currently among the best in terms of specificity (but
less so in sensitivity) for X4 viruses.46 In fact, a subset of
35 individuals tested in parallel with the VMS genotypic soft-
ware and the Eurofins-Viralliance assay showed highly concor-
dant results (86%). In fact, only the five specimens with
disagreement were shown to have X4/R5 dual viruses in the phe-
notypic test when the genotypic analyses predicted the presence
of R5 viruses alone. Sampling variability in the genetic amplifi-
cation process could somewhat explain this discordance.47
Taking into account these findings, our estimates on the preva-
lence of X4 viruses should be considered as conservative. It is
noteworthy that the 18% prevalence of X4 in recent seroconver-
ters is very similar to that reported in chronically
HIV-1-infected, drug-naive patients.18,23,24 Therefore, we are
confident about the lack of association between co-receptor
tropism and drug resistance mutations, CD4 counts and viral
load in our population of recent HIV-1 seroconverters.
In summary, a significant proportion of recent HIV-1 sero-
converters harbour X4 viruses. This observation may have
important clinical and therapeutic implications, since X4
viruses are associated with more rapid disease progression26
and because CCR5 antagonists might be harmful in this
population.48 Contrary to recent concerns,10 transmission of
drug-resistant viruses does not seem to be associated with
HIV-1 co-receptor usage.
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